Brentuximab-induced colitis in a non-stem-cell transplant patient

Authors

Sareena Ali, Advocate Aurora HealthFollow
Sufyan AbdulMujeeb, Advocate Aurora HealthFollow
Ahmed Khattab, Advocate Aurora HealthFollow
Nahren Asado, Advocate Aurora HealthFollow
Marc Fine, Advocate Aurora HealthFollow

Recommended Citation

Ali S, AbdulMujeeb S, Khattab A, Asado N, Fine M. Brentuximab-Induced Colitis in a Non-Stem-Cell Transplant Patient. ACG Case Rep J. 2023;10(1):e00974. Published 2023 Jan 25. doi:10.14309/crj.0000000000000974

Affiliations

Advocate Lutheran General Hospital

Abstract

Many chemotherapeutic agents have been associated with drug-induced colitis (DIC). With newer agents' expansion of approval as first-line therapy for common cancers, it is important to be cognizant of their association with DIC. We present a case of brentuximab-associated DIC in an elderly woman with CD30+ Hodgkin lymphoma. Brentuximab's association with DIC was suspected by others in the literature, but a history of stem-cell transplant in them would blur the association with graft-vs-host disease. Lack of stem-cell transplant in our patient makes the link between brentuximab and DIC unambiguous.

Type

Article

PubMed ID

36713279